Cardizem (R) (Diltiazem HC1 for injection) Monvial (R)
Company: Hoechst Marion Roussel
Approval Status: Approved September 1997
Treatment for: atrial fibrillation
Areas: Cardiology/Vascular Diseases
| General Information | Side Effects |
General Information
Hoeschst Marion Roussel announced that Cardizem (R) (diltiazem HC1 for injection) Monovial (R) has been cleared for use in the U.S. by the FDA. Cardizem Monovial is an advanced infusion delivery system for Cardizem Injectable, a widely prescribed compound for treatment of certain heartbeat irregularities.
Cardizem Monovial is indicated for maintenance heart rate control in patients with atrial fibrillation or atrial flutter for up to 24 hours. Cardizem Monovial is expected to be available beginning in early 1998.
Side Effects
The most commonly reported adverse events are asymptomatic hypotension (4.3%), symptomatic hypotension (3.2%), injection site reaction (3.9%), flushing (1.7%), and arrhythmia (1.0%).
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
